Therapeutic Inhibition of Platelet Function in Stroke

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

1994 • 3,408 citations

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1996 • 2,812 citations

Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty

1994 • 2,614 citations

Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2

1996 • 1,987 citations

Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

1997 • 1,922 citations

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke

1997 • 1,840 citations

Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina

1983 • 1,740 citations

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

1978 • 1,559 citations

European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

1997 • 1,389 citations

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study

1997 • 1,346 citations

A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients

1989 • 1,209 citations

CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke

1997 • 1,200 citations

Acetylation of prostaglandin synthase by aspirin.

1975 • 1,003 citations

Platelet-Active Drugs

2001 • 993 citations

Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty

1997 • 950 citations

THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE

1989 • 912 citations

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.

1975 • 856 citations

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1994 • 852 citations

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II

1997 • 821 citations

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

1983 • 780 citations

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

1997 • 775 citations

Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine

1995 • 769 citations

A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic Stroke

1991 • 747 citations

Dose-Related Kinetics of Aspirin

1984 • 552 citations

Inhibition of platelet prostaglandin synthetase by oral aspirin.

1978 • 552 citations

Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles.

1997 • 486 citations

Clinical pharmacology of platelet cyclooxygenase inhibition.

1985 • 432 citations

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1994 • 425 citations

Development of aspirin resistance in persons with previous ischemic stroke.

1994 • 412 citations

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1996 • 404 citations

Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa.

1993 • 369 citations

Suppression of Thromboxane A₂but Not of Systemic Prostacyclin by Controlled-Release Aspirin

1991 • 333 citations

Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade

1998 • 293 citations

The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

1994 • 289 citations

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors

1992 • 288 citations

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

1995 • 282 citations

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

1997 • 273 citations

Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy

1997 • 235 citations

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

1996 • 231 citations

Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent

1993 • 226 citations

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1995 • 214 citations

Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.

1995 • 209 citations

Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.

1992 • 202 citations

Aspirin, platelets, and thrombosis: theory and practice

1994 • 196 citations

Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression.

1980 • 195 citations

Low molecular weight, non-peptide fibrinogen receptor antagonists

1992 • 190 citations

Influence of Blockade at Specific Levels of the Coagulation Cascade on Restenosis in a Rabbit Atherosclerotic Femoral Artery Injury Model

1995 • 189 citations

Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial.

1993 • 189 citations

Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina

1996 • 186 citations

Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome

1998 • 180 citations

Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

1994 • 179 citations

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.

1993 • 170 citations

Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial

1990 • 161 citations

Intracoronary stenting without coumadin: One month results of a French multicenter study

1995 • 157 citations

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men

1994 • 132 citations

Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.

1989 • 120 citations

Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.

1994 • 120 citations

First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade

1997 • 118 citations

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

1993 • 107 citations

Platelet Activation and Lipid Peroxidation in Patients With Acute Ischemic Stroke

1997 • 99 citations

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results.

1988 • 94 citations

Evidence for episodic platelet activation in acute ischemic stroke.

1994 • 84 citations

Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion

1996 • 83 citations

Dipyridamole alone or combined with low‐dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo [see comments]

1990 • 83 citations

Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation

1997 • 73 citations

Clopidogrel: An Antithrombotic Drug Acting on the ADP-dependent Activation Pathway of Human Platelets

1996 • 56 citations

Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin.

1993 • 48 citations

Ticlopidine: a new platelet aggregation inhibitor.

1992 • 46 citations

Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation

1995 • 30 citations

Ro 44-9883, a New Non-Peptidic GPIIb-GPIIIa Antagonist Prevents Platelet Loss in a Guinea Pig Model of Extracorporeal Circulation

1993 • 24 citations

Abciximab-Associated Profound Thrombocytopenia: Therapy With Immunoglobulin and Platelet Transfusion

1996 • 19 citations

Antiplatelet Effects of the Addition of Acetylsalicylic Acid 40 Mg Daily to Ticlopidine in Human Healthy Volunteers

1997 • 17 citations

Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes

1998 • 5 citations

Clinical efficacy of integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: the PURSUIT trial

1998 • 2 citations

Cited By (0)

Loading...